Waters Corporation (WAT) Q1 2008 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 29, 2008. Waters Corporation designs, manufactures, and services analytical instrument systems, including high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC), mass spectrometry (MS), and thermal analysis instruments. The company operates through two primary divisions: the Waters Division and the TA Division.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Total Net Sales | $371.7 million | $330.8 million |
| Gross Profit | $216.3 million | $187.5 million |
| Gross Margin | 58.2% | 56.7% |
| Operating Income | $88.4 million | $72.8 million |
| Net Income | $68.5 million | $55.9 million |
| Diluted EPS | $0.67 | $0.54 |
| Cash from Operations | $95.9 million | $82.7 million |
| Cash & Equivalents | $700.6 million | $597.3 million |
| Total Debt | $929.3 million | $865.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12% year-over-year, driven by a 12% increase in product sales and a 14% increase in service sales. Foreign currency translation positively impacted sales growth by 6%.
- Profitability: Operating income rose 21% to $88.4 million, and net income increased 22% to $68.5 million. Gross margin expanded to 58.2% due to lower manufacturing costs, favorable product mix, and currency benefits.
- Segment Performance: The Waters Division grew 12%, fueled by ACQUITY UPLC and Synapt HDMS systems. The TA Division grew 17%, attributed to new product introductions and the acquisition of Calorimetry Sciences Corporation.
- Debt Structure: In March 2008, the company entered a new $150 million term loan facility (2008 Credit Agreement) to repay amounts under its revolving credit facility. Total debt increased to $929.3 million, with a weighted-average interest rate of 4.30%.
- Share Repurchases: The company repurchased 1.3 million shares for $74.8 million during the quarter.
Outlook, Risks, and Commentary
- Management Commentary: Management expects selling and administrative expenses to grow at a slightly lower rate for the remainder of 2008. The company anticipates contributing $3.5 million to $7.0 million to defined benefit pension plans in fiscal 2008.
- Liquidity: With $758.5 million in cash and short-term investments and $348.5 million in available borrowing capacity, management believes liquidity is sufficient for working capital, capital spending, and potential acquisitions for the next 12 months.
- Risks: Key risks include reliance on pharmaceutical and biotechnology customers (approx. 52% of sales), foreign exchange rate fluctuations (70% of sales are outside the U.S.), and potential disruptions in global manufacturing facilities. The company also faces risks related to intellectual property litigation and regulatory compliance.
- Unusual Items: A one-time $12.6 million pension benefit payment was made to the Waters Employee Investment Plan in Q1 2008, impacting cash flows from operating activities.
Investor Verification Checklist
- Verify the sustainability of the 12% sales growth, particularly the contribution from foreign currency translation versus organic demand.
- Monitor the impact of the new $150 million term loan on future interest expense and leverage ratios.
- Assess the Days Sales Outstanding (DSO) increase to 78 days and its effect on future cash collections.
- Review the concentration of sales to the pharmaceutical industry and potential exposure to capital spending cuts in that sector.
- Confirm the status of ongoing litigation and intellectual property claims as disclosed in the risk factors.